Epstein-Barr virus infection

This early-stage trial tests a vaccine called OSU-2131, designed to help the immune system fight Epstein-Barr virus (EBV). EBV can cause cancers in people who have weakened immune systems, such as those awaiting organ transplants. The study includes healthy volunteers and transpl…

This early-stage study is testing two new vaccines (V350A and V350B) designed to prevent diseases caused by the Epstein-Barr virus (EBV), which can cause infectious mononucleosis and is linked to certain cancers and multiple sclerosis. The study will enroll 250 healthy adults and…

This study tests two experimental vaccines against Epstein-Barr virus (EBV), which causes mono and is linked to cancers. Researchers will give 750 healthy adults aged 18-29 three shots over several months to check for side effects and immune response. The goal is to find a safe v…

This early-stage trial is testing an mRNA vaccine called mRNA-1189 to see if it is safe and triggers an immune response against Epstein-Barr virus (EBV). EBV is a common virus that can cause mononucleosis and is linked to certain cancers. The study involves 120 healthy adults age…

This phase 2 trial tests whether the drug nivolumab can slow or stop the growth of Epstein-Barr virus (EBV)-positive lymphoproliferative disorders and non-Hodgkin lymphomas. About 40 people aged 12 and older whose cancers have not responded to standard therapy will receive nivolu…

This early-stage trial tests whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have aggressive B-cell non-Hodgkin lymphoma. About 25 adults with high-risk features will receive up to 6 cycles of…

This early-phase trial tests a treatment called LB-DTK-MV, which uses immune cells from a healthy donor to fight three viruses (CMV, BKV, and EBV) that have become resistant to standard antiviral drugs. The study includes 27 adults who have had a stem cell transplant or certain c…

This early-phase trial tests a new type of immune cell therapy for patients with EBV-positive Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard treatments. The researchers add a gene called C7R to the patient's own T cells to help them survive longer …

This study tests whether giving patients special donor immune cells (called CD45RA-depleted DLI) can treat viral infections that persist after a stem cell transplant. The trial involves 30 participants who have not improved with standard antiviral drugs. Researchers will measure …

This early-phase trial is testing an oral drug called VK-2019 in 30 adults with a type of lymphoma (DLBCL) that is linked to the Epstein-Barr virus and has not responded to at least two prior treatments. Participants take the drug daily in 28-day cycles at one of three dose level…

This trial investigates whether specially grown immune cells, called pathogen-specific cytotoxic T lymphocytes (CTLs), can safely and effectively treat stubborn infections like EBV, CMV, and adenovirus in people with weakened immune systems, such as stem cell or organ transplant …

This study looks at whether people with a type of throat cancer linked to the Epstein-Barr virus can safely receive lower doses of radiation after initial chemotherapy. The goal is to see if reducing radiation can still control the cancer while causing fewer long-term side effect…

This early-phase study tests whether specially trained immune cells from healthy donors can safely treat viral infections (EBV, CMV, adenovirus, BK virus) in patients who have had a stem cell transplant or certain CAR-T therapy. These infections can be life-threatening when the i…

This early-stage trial tests whether specially grown immune cells from a donor can safely help transplant patients fight off viral infections that standard treatments can't control. The cells target Epstein-Barr virus, cytomegalovirus, adenovirus, and BK virus. Up to 36 adults wh…

This phase 3 trial tests tabelecleucel, a cell therapy made from donor immune cells, in 115 organ or stem cell transplant patients who developed a rare cancer (EBV+ PTLD) after standard treatment failed. The goal is to see if it can shrink tumors and improve outcomes. Participant…

This study tests whether using early drug monitoring and a dose-adjustment calculator can help infants under 90 days old with sepsis reach target vancomycin levels more quickly. Currently, doctors must wait 24-48 hours to check drug levels, which can delay effective treatment. Th…

This early-phase trial tests whether specially engineered immune cells (EBV-TCR-T cells) can safely control Epstein-Barr virus infections in people who have had a stem cell transplant. About 12 participants will receive one to three infusions of donor-derived cells. The main goal…

This study tests whether giving patients donor-derived immune cells (VSTs) on a regular schedule can prevent dangerous viral infections after a stem cell transplant. 180 participants will be randomly assigned to receive VSTs either on a fixed schedule or only when a virus is dete…

This study compares two ways of giving the antibiotic cefepime to very sick patients with sepsis in the ICU. The new method adjusts the dose based on the patient's kidney function, using only standard doses. The main goal is to see if this approach is easy for doctors to use and …

This study tests whether combining two drugs, golidocitinib and selinexor, can control chronic active Epstein-Barr virus disease (CAEBVD). Researchers will enroll 28 adults with CAEBVD and track how well the treatment reduces symptoms and lowers virus levels in the blood. It is a…

This early-phase study tests a new treatment for Epstein-Barr virus (EBV) that can occur after a stem cell transplant. The treatment uses specially engineered immune cells (EBV-TCR-T cells) to find and destroy virus-infected cells. Up to 18 adult patients who have persistent EBV …

This study tests if valacyclovir works as well as valganciclovir to prevent CMV and EBV infections in kidney transplant patients. Valganciclovir can cause bone marrow suppression, a serious side effect. The study will enroll 80 kidney transplant recipients and monitor them for ne…

This study tests whether specially grown immune cells from an unrelated donor can safely treat viral infections in people with weakened immune systems, such as after a stem cell transplant. About 750 participants will receive these cells and be monitored for side effects like inf…

This study tests whether specially grown donor immune cells (viral-specific T-cells) can safely treat viral infections that often occur after a stem cell transplant. These infections can be serious and sometimes don't respond to standard antiviral drugs. The approach aims to boos…

This study tests whether giving zinc supplements along with standard antibiotics can reduce deaths and improve recovery in young infants (0-59 days old) hospitalized with severe infections like sepsis or pneumonia. About 3,250 babies in Tanzania will receive either zinc or a plac…

This study looks at people who have had unusually severe or long-lasting viral infections, like serious cases of herpes, HPV, or the flu. Researchers want to find out if these people have hidden immune system or genetic problems that make them more vulnerable. Up to 600 participa…

This study collects blood, bone marrow, and tissue samples from people with HIV, KSHV, or certain cancers to help researchers learn more about these diseases. Participants must be 18 or older and may have HIV, KSHV, or related conditions. No treatment is given; the goal is to gat…

This study looks at how the immune system changes with age and how that affects the risk of infections in people 60 and older. Researchers will collect blood, urine, stool, and other samples from elderly patients with infections and healthy older adults. By analyzing immune cells…

This study aims to improve how doctors evaluate and manage people who have been exposed to bioterrorism agents (like anthrax) or emerging infectious diseases (like SARS or new flu strains). Up to 200 participants, including patients and healthcare workers, will be monitored and t…

This study aims to find genetic mutations that cause chronic active Epstein-Barr virus (CAEBV), a rare and serious disease mainly affecting children and young adults. Researchers will analyze blood and tissue samples from up to 50 patients and 150 relatives, plus anonymous donor …

This study looks at why some teenagers and young adults feel tired for months after getting Epstein-Barr virus (the virus that causes mono). Researchers will follow 150 infected people and 150 healthy people for six months, using brain scans, immune tests, and questionnaires. The…

This study tests a new, lightweight ultrasound device called NeoDoppler that can be gently placed on a newborn's soft spot (fontanelle) to continuously measure blood flow in the brain. Researchers will enroll 180 preterm and full-term infants, including those with conditions like…

This study is looking at whether early signs of inflammation in the blood can help identify which patients with infections are at risk for serious complications like sepsis. Researchers will follow 4,200 adults with confirmed or suspected infections, as well as healthy controls, …

This study looks at how the antibiotic ceftazidime avibactam behaves in 30 children with severe infections who are in intensive care, some on life support. Researchers will measure drug levels in the blood to understand the right dose. The goal is to improve treatment for life-th…

This study looks at how the antifungal medicine caspofungin behaves in children with severe infections, especially those with liver problems or on life support like ECMO. Researchers will measure drug levels in the blood to understand dosing needs. About 60 children in intensive …

This study will collect data from 2,000 children admitted to pediatric intensive care units (PICUs) with severe infections across major Chinese cities. Over 10 years, researchers will track which germs cause these infections, how they are treated, and patient outcomes. The goal i…

This study looks at two common antibiotic combinations given to hospitalized adults with infections: vancomycin plus piperacillin-tazobactam, or vancomycin plus cefepime. The goal is to see if one is less likely to cause kidney injury than the other, using more sensitive markers …

This study will test 10,000 people in Cambodia for 57 different infectious diseases, including dengue, flu, and malaria. Researchers want to understand how these diseases spread and who is at risk. The goal is to give local health authorities the information they need to create b…

This pilot study is testing whether a smart wristband can accurately measure drug levels in sweat compared to standard blood tests. Researchers will collect sweat, saliva, and blood samples from 100 patients with chronic or infectious diseases who are taking medications like cycl…

This study is looking for new ways to diagnose sepsis, a life-threatening reaction to infection, earlier in the emergency room. Researchers will study the immune responses of 3,300 adults with suspected infections to find patterns that signal sepsis. The goal is to improve diagno…